Nemaura Pharma Limited Awarded the Prestigious 2016 Frost & Sullivan Award for Best Practices in Enabling Technology Leadersh...
August 15 2016 - 6:13PM
Business Wire
Nemaura Pharma has been awarded the prestigious 2016 Frost &
Sullivan award for best practices in Enabling Technology Leadership
in the Transdermal Drug Delivery Industry.
The analysts stated that, “Nemaura Pharma’s drug delivery
technology has revolutionized the way drugs are delivered in the
healthcare system.” They spoke highly of Nemaura's Memspatch liquid
delivery system because it is highly accurate, easy to use, and
patient-friendly. The Memspatch uses microneedle technology to
insert several small needles no more than few millimetres into the
skin. The dose is dispersed over a larger surface area than is
possible with a single needle, facilitating faster absorption. The
judges pointed out that Nemaura has overcome the problem of erratic
dosing that has dogged traditional transdermal patches by adding an
applicator to the system—this allows for 100% needle
penetration.
“Conventional liquid vaccine has contamination and stability
risks associated with it,” said Frost & Sullivan Senior
Research Analyst Debarati Sengupta. “Nemaura Pharma has
reformulated the liquid vaccine into a stable, solid dose
formulation, without any loss of potency.” The Micro-Patch system
works by inserting a super-sharp stainless steel needle into the
outer layer of the skin. The needle then retracts completely,
minimising the risk of stick injuries, and the solid dose
formulation remains deposited in the skin. The judges noted that
the system eliminates the need for cold-chain storage, which should
lead to significant savings and does not require a specialist to
use it to administer the drug.
“The solid and liquid microneedle-based drug delivery
technologies (Memspatch and Micro-Patch) provide pain-free,
minimally-invasive drug delivery with controlled drug dosage,”
noted Debarati. “With superior drug absorption, reduced or minimal
drug stability or dosage issues, this easy-to-use transdermal
technology drives better patient compliance and outcomes. With its
strong overall performance, Nemaura Pharma has earned Frost &
Sullivan's 2016 Enabling Technology Leadership Award.”
The award was made after an in-depth evaluation by Frost &
Sullivan analysts, including a review by a panel of industry
experts. “We are delighted and honoured to receive this accolade,”
said Dr Faz Chowdhury, CEO of Nemaura Pharma. “We have worked over
several years to carefully integrate human factors into what we
envisage will become the world's leading injectable devices for a
very wide range of drugs, and we anticipate this will enable
patients globally to benefit from less intrusive and more intuitive
devices for the routine administration of vaccines and
medicines.”
Notes for Editors.
About Nemaura Pharma Limited
A private specialist biotech company, Nemaura Pharma is
strategically positioned to work with global pharmaceutical
companies, as well as new biotechnology companies, to successfully
bring both new and old drugs to patients in superior delivery
formulations and systems. Ultimately, we aim to improve patient
lifestyle and quality of life. Our advanced drug delivery systems
are designed to increase the effectiveness and safety of
therapeutic drugs, while also reducing complications due to patient
non-compliance, and mitigating the side effects of less efficient
delivery systems.
www.nemaura.co.uk
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in
collaboration with clients to leverage visionary innovation that
addresses the global challenges and related growth opportunities
that will make or break today's market participants. For more than
50 years, we have been developing growth strategies for the Global
1000, emerging businesses, the public sector and the investment
community.
http://ww2.frost.com/
Cautionary Statement Regarding Forward Looking Statements.
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160815006206/en/
Nemaura Pharma LimitedDavid Scott, + 44 1509 222
912bd@nemaura.co.uk